Across TCGA pan-cancer cohorts, ANXA6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANXA6 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANXA6 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ANXA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and STAD are the cancer types where ANXA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.651	.012	20	view →
LUAD	OS	Median	All	0.090	0.788	<.001	16	view →
STAD	DFS	Median	All	0.210	0.709	.010	9	view →
LGG	OS	Median	All	0.294	0.799	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANXA6 tumor-vs-normal RNA expression · all ANXA6 data types